Literature DB >> 9741353

Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin).

D Nachbaur1, M Herold, A Gächter, D Niederwieser.   

Abstract

The mode of action of intravenous immunoglobulins (IVIG) in autoimmune and immunoregulatory disorders is still poorly understood. In vitro, direct effects of IVIG on cytokine release and on cytokine receptors have been described, as well as naturally occurring, neutralizing anticytokine antibodies. The aim of our study was to investigate whether the enrichment in IgM and IgA would have any impact on the in vitro immunomodilatory capacity of IVIG. The preparation tested (Pentaglobin) contains 76% IgG and 12% IgM and IgA, respectively. We could demonstrate a significant inhibition of alloantigen-induced proliferation in the mixed lymphocyte reaction (MLR) even at a Pentaglobin concentration of 1.0 mg/ml. About 10-fold higher concentrations of standard 7S IVIG containing only trace amounts of IgM and IgA were necessary to achieve equivalent suppression of the alloimmune response. Similarly, phytohaemagglutinin (PHA)-induced lymphocyte proliferation was more effectively inhibited by Pentaglobin than by standard 7S IVIG. Cytokine analyses in culture supernatants of MLR provide evidence that Pentaglobin not only modulates interleukin-2 (IL-2), which has already been observed with standard 7S IVIG, but, moreover, modulates interferon-gamma production with a subsequent impact on monocyte-derived tumour necrosis factor-alpha and IL-6 release. Based on these results we conclude that in vitro the IgM- and IgA-enriched Pentaglobin has a more potent immunomodulatory capacity than conventionally used standard 7S IVIG.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9741353      PMCID: PMC1364217          DOI: 10.1046/j.1365-2567.1998.00495.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab')2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation.

Authors:  D Nachbaur; M Herold; B Eibl; H Glassl; H Schwaighofer; C Huber; A Gächter; M Pichl; D Niederwieser
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

Review 2.  Manipulating the immune system with immune globulin.

Authors:  J M Dwyer
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

Review 3.  Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.

Authors:  S V Kaveri; G Dietrich; V Hurez; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

4.  The treatment of Kawasaki syndrome with intravenous gamma globulin.

Authors:  J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

5.  Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation.

Authors:  E Holler; H J Kolb; A Möller; J Kempeni; S Liesenfeld; H Pechumer; W Lehmacher; G Ruckdeschel; B Gleixner; C Riedner
Journal:  Blood       Date:  1990-02-15       Impact factor: 22.113

6.  The role of adherent HLA-DR+ mononuclear cells in autologous and allogeneic MLR.

Authors:  C Huber; U Fink; W Leibold; F Schmalzl; P A Peterson; L Klareskog; H Braunsteiner
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

7.  Use of an immunoglobulin preparation enriched for IgM (Pentaglobin) for the treatment of acute graft-versus-host disease.

Authors:  H G Klingemann; M J Barnett; D E Reece; J D Shepherd; G L Phillips
Journal:  Bone Marrow Transplant       Date:  1990-09       Impact factor: 5.483

8.  Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages.

Authors:  D Niederwieser; M Herold; W Woloszczuk; W Aulitzky; B Meister; H Tilg; G Gastl; R Bowden; C Huber
Journal:  Transplantation       Date:  1990-10       Impact factor: 4.939

9.  Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease.

Authors:  V Hurez; M D Kazatchkine; T Vassilev; S Ramanathan; A Pashov; B Basuyaux; Y de Kozak; B Bellon; S V Kaveri
Journal:  Blood       Date:  1997-11-15       Impact factor: 22.113

10.  Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation.

Authors:  C H Poynton; S Jackson; C Fegan; R A Barnes; J A Whittaker
Journal:  Bone Marrow Transplant       Date:  1992-06       Impact factor: 5.483

View more
  8 in total

1.  IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice.

Authors:  T Vassilev; N Mihaylova; E Voynova; M Nikolova; M Kazatchkine; S Kaveri
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

2.  Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates.

Authors:  K S Sivasai; T Mohanakumar; D Phelan; S Martin; M E Anstey; D C Brennan
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

3.  Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study.

Authors:  Tim Rahmel; Felix Kraft; Helge Haberl; Ute Achtzehn; Timo Brandenburger; Holger Neb; Dominik Jarczak; Maximilian Dietrich; Harry Magunia; Frieda Zimmer; Jale Basten; Claudia Landgraf; Thea Koch; Kai Zacharowski; Markus A Weigand; Peter Rosenberger; Roman Ullrich; Patrick Meybohm; Axel Nierhaus; Detlef Kindgen-Milles; Nina Timmesfeld; Michael Adamzik
Journal:  Crit Care       Date:  2022-07-07       Impact factor: 19.334

Review 4.  Best-practice IgM- and IgA-enriched immunoglobulin use in patients with sepsis.

Authors:  Axel Nierhaus; Giorgio Berlot; Detlef Kindgen-Milles; Eckhard Müller; Massimo Girardis
Journal:  Ann Intensive Care       Date:  2020-10-07       Impact factor: 6.925

Review 5.  Sepsis-Pathophysiology and Therapeutic Concepts.

Authors:  Dominik Jarczak; Stefan Kluge; Axel Nierhaus
Journal:  Front Med (Lausanne)       Date:  2021-05-14

6.  The use of high-dose immunoglobulin M-enriched human immunoglobulin in dogs with immune-mediated hemolytic anemia.

Authors:  Jason P Bestwick; Mellora Sharman; Nat T Whitley; Caroline Kisielewicz; Barbara J Skelly; Simon Tappin; Lindsay Kellett-Gregory; Mayank Seth
Journal:  J Vet Intern Med       Date:  2021-11-15       Impact factor: 3.333

Review 7.  Use of Intravenous Immunoglobulins in Sepsis Therapy-A Clinical View.

Authors:  Dominik Jarczak; Stefan Kluge; Axel Nierhaus
Journal:  Int J Mol Sci       Date:  2020-08-03       Impact factor: 5.923

8.  The Functional Role of IgA in the IgM/IgA-Enriched Immunoglobulin Preparation Trimodulin.

Authors:  Fabian Bohländer; Sabrina Weißmüller; Dennis Riehl; Marcus Gutscher; Jörg Schüttrumpf; Stefanie Faust
Journal:  Biomedicines       Date:  2021-12-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.